SCHEMBL940648

SCHEMBL940648

CC(C)(C)OC(=O)N1CCC(Oc2ccc(Br)cn2)CC1

nearest known ligand 0.66

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 15/20 0.66
DGAT1 O75907 1/20 0.61
NPBWR1 P48145 1/20 0.47
MCHR1 Q99705 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30427128 1.00 GPR119 (0.66) GPR119DGAT1NPBWR1MCHR1
SCHEMBL20120962 0.91 GPR119 (0.64) GPR119DGAT1
SCHEMBL29547496 0.91 GPR119 (0.64) GPR119DGAT1
SCHEMBL20120507 0.91 GPR119 (0.64) GPR119DGAT1
SCHEMBL31583439 0.89 GPR119 (0.56) GPR119DGAT1
SCHEMBL31401120 0.88 DGAT1 (0.57) GPR119DGAT1
SCHEMBL15525341 0.88 DGAT1 (0.57) GPR119DGAT1
SCHEMBL13993542 0.87 GPR119 (0.67) GPR119NPBWR1MCHR1
SCHEMBL31748202 0.87 GPR119 (0.67) GPR119DGAT1NPBWR1MCHR1
SCHEMBL20233853 0.86 GPR119 (0.52) GPR119DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570662-B2 Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases NURIX THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
US-20250257035-A1 1,4-Substituted Piperidine Derivatives CEPHALON LLC 2025-08-14 US disclosed
EP-4512402-A2 BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF Nurix Therapeutics, Inc. (US) 2025-02-26 EP disclosed
EP-4367118-B1 BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF NURIX THERAPEUTICS INC (US) 2025-01-29 EP disclosed
US-20240417402-A1 SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES GILEAD SCIENCES, INC. 2024-12-19 US disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF NURIX THERAPEUTICS INC (US) 2024-12-05 US disclosed
US-12098130-B2 1,4-substituted piperidine derivatives 89BIO LTD (IL) 2024-09-24 US disclosed
EP-4430052-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF Nurix Therapeutics, Inc. (US) 2024-09-18 EP disclosed
US-12091426-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof NURIX THERAPEUTICS, INC. (US) 2024-09-17 US disclosed
WO-2003053925-A1 PYRROLIDINE-2-ONES AS FACTOR XA INHIBITORS GLAXO GROUP LIMITED (GB) 2003-07-03 WO disclosed
EP-1282614-A1 HYDROXAMIC ACID DERIVATIVES Darwin Discovery Limited (GB) 2003-02-12 EP disclosed
WO-2003010158-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2003-02-06 WO disclosed
WO-2002074767-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
US-20020037900-A1 Hydroxamic acid derivatives DARWIN DISCOVERY LIMITED (GB) 2002-03-28 US disclosed
WO-2001087870-A1 HYDROXAMIC ACID DERIVATIVES DARWIN DISCOVERY LIMITED (GB) 2001-11-22 WO disclosed
US-6313127-B1 FOR THERAPY OF HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS ZENECA LIMITED (GB) 2001-11-06 US disclosed
EP-0880501-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS ZENECA LIMITED (GB) 1998-12-02 EP disclosed
WO-1997028128-A1 HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS ZENECA LIMITED (GB) 1997-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250257035-A1 1,4-Substituted Piperidine Derivatives FASN, CES1, CPT1A GPR119 223/4885DGAT1 106/4885NPBWR1 1725/4885
US-12570662-B2 Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases IRAK1, IRAK2, IRAK4 GPR119 2560/4885DGAT1 4132/4885NPBWR1 1600/4885
US-20240417402-A1 SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES IRAK1, IRAK2, IRAK4 GPR119 3465/4885DGAT1 4502/4885NPBWR1 703/4885
US-20020037900-A1 Hydroxamic acid derivatives ADAM17, ADAM10, ADAM33 GPR119 4313/4885DGAT1 538/4885NPBWR1 4490/4885
US-12098130-B2 1,4-substituted piperidine derivatives FASN, CES1, CPT1A GPR119 223/4885DGAT1 106/4885NPBWR1 1725/4885
US-12091426-B2 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof TTK, HIPK1, CLK1 GPR119 3689/4885DGAT1 3397/4885NPBWR1 3411/4885
US-20240400587-A1 BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF TTK, HIPK1, CLK1 GPR119 3689/4885DGAT1 3397/4885NPBWR1 3411/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 GPR119 1372/4885DGAT1 4613/4885NPBWR1 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.